Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.

Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK.

Thorax. 2012 Nov;67(11):977-84. doi: 10.1136/thoraxjnl-2012-201945. Epub 2012 Aug 31.

2.

Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.

Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, Shimizu W.

Int J Chron Obstruct Pulmon Dis. 2015 Mar 5;10:515-23. doi: 10.2147/COPD.S79942. eCollection 2015.

3.

Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.

Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB.

Thorax. 2008 Apr;63(4):301-5. Epub 2007 Oct 19.

PMID:
17951276
4.

Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease.

Lindenauer PK, Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Hill NS.

JAMA Intern Med. 2014 Dec;174(12):1982-93. doi: 10.1001/jamainternmed.2014.5430.

5.

Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).

Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM.

Am J Cardiol. 2013 Feb 15;111(4):582-7. doi: 10.1016/j.amjcard.2012.10.041. Epub 2012 Nov 29.

PMID:
23200803
6.

Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease.

Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK.

JAMA. 2010 May 26;303(20):2035-42. doi: 10.1001/jama.2010.672.

PMID:
20501925
7.

Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.

Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS.

J Am Coll Cardiol. 2010 Apr 27;55(17):1780-7. doi: 10.1016/j.jacc.2010.01.024.

8.

β-blockers for COPD inpatients.

Suissa S, Ernst P.

Thorax. 2012 Nov;67(11):936-7. doi: 10.1136/thoraxjnl-2012-202471. No abstract available.

PMID:
23100217
9.

Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease.

Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB.

JAMA. 2010 Jun 16;303(23):2359-67. doi: 10.1001/jama.2010.796.

PMID:
20551406
10.

Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.

Du Q, Sun Y, Ding N, Lu L, Chen Y.

PLoS One. 2014 Nov 26;9(11):e113048. doi: 10.1371/journal.pone.0113048. eCollection 2014.

11.

Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.

Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM.

Pharmacotherapy. 2007 May;27(5):684-90.

PMID:
17461703
12.

Combination antihypertensive therapy among patients with COPD.

Herrin MA, Feemster LC, Crothers K, Uman JE, Bryson CL, Au DH.

Chest. 2013 May;143(5):1312-1320. doi: 10.1378/chest.12-1770.

PMID:
23287970
13.

Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States.

Rohde LE, Clausell N, Ribeiro JP, Goldraich L, Netto R, William Dec G, DiSalvo TG, Polanczyk CA.

Int J Cardiol. 2005 Jun 22;102(1):71-7.

PMID:
15939101
14.

Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure.

Bhatia V, Bajaj NS, Sanam K, Hashim T, Morgan CJ, Prabhu SD, Fonarow GC, Deedwania P, Butler J, Carson P, Love TE, Kheirbek R, Aronow WS, Anker SD, Waagstein F, Fletcher R, Allman RM, Ahmed A.

Am J Med. 2015 Jul;128(7):715-21. doi: 10.1016/j.amjmed.2014.11.036. Epub 2014 Dec 30.

PMID:
25554369
16.

Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease.

Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrús A, Torres A, Miravitlles M.

Respiration. 2012;84(1):17-26. doi: 10.1159/000335467. Epub 2012 Feb 11.

PMID:
22327370
17.

β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations.

Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM.

Ann Pharmacother. 2013 May;47(5):651-6. doi: 10.1345/aph.1R600. Epub 2013 Apr 12.

PMID:
23585645
18.

Cardioselective beta-blockers for reversible airway disease.

Salpeter S, Ormiston T, Salpeter E.

Cochrane Database Syst Rev. 2002;(4):CD002992. Review.

PMID:
12519582
19.

Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study.

Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ.

BMJ. 2011 May 10;342:d2549. doi: 10.1136/bmj.d2549.

20.

Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study.

Johannesdottir SA, Christiansen CF, Johansen MB, Olsen M, Xu X, Parker JM, Molfino NA, Lash TL, Fryzek JP.

J Med Econ. 2013 Jul;16(7):897-906. doi: 10.3111/13696998.2013.800525. Epub 2013 May 23.

PMID:
23621504

Supplemental Content

Support Center